Spots Global Cancer Trial Database for dalpiciclib
Every month we try and update this database with for dalpiciclib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer | NCT05512780 | Solid Tumor | Dalpiciclib | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC | NCT05228951 | Breast Cancer | Pyrotinib malea... | 18 Years - 75 Years | Shengjing Hospital | |
| Dalpiciclib in HR+/HER2- ABC | NCT06301438 | Advanced Breast... | dalpiciclib | 18 Years - | RenJi Hospital | |
| Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer | NCT05463601 | Metastatic Brea... | Mecapegfilgrast... dalpiciclib exemestane, ful... | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer | NCT05578053 | Breast Cancer | Dalpiciclib | 18 Years - | Hebei Medical University Fourth Hospital | |
| Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer | NCT05463601 | Metastatic Brea... | Mecapegfilgrast... dalpiciclib exemestane, ful... | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） | NCT06107673 | Breast Cancer | Dalpiciclib Aromatase inhib... Docetaxel injec... Epirubicin Hydr... Cyclophosphamid... | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma | NCT05952128 | Sarcoma | Fluzoparib+ Dal... | 12 Years - 75 Years | Sun Yat-sen University | |
| Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer | NCT06341894 | Early Breast Ca... | Dalpiciclib Endocrine thera... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | NCT05582499 | Breast Neoplasm Breast Cancer Breast Tumors Triple-Negative... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Dalpiciclib Pyrotinib SHR-A1811 SHR-1316 Camrelizumab Trophoblast cel... Pertuzumab Trastuzumab Goserelin Letrozole Nab paclitaxel Carboplatin Epirubicin Cyclophosphamid... Fluzoparib HER2 ADC | 18 Years - 70 Years | Fudan University | |
| Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer | NCT05638594 | Breast Cancer | Pyrotinib Trastuzumab Dalpiciclib Letrozole Pertuzumab Docetaxel Carboplatin Gonadotropin-re... | 18 Years - 75 Years | Shengjing Hospital | |
| Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） | NCT06107673 | Breast Cancer | Dalpiciclib Aromatase inhib... Docetaxel injec... Epirubicin Hydr... Cyclophosphamid... | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy | NCT05806671 | Breast Cancer | Dalpiciclib Pyrotinib Fulvestrant | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer | NCT05512780 | Solid Tumor | Dalpiciclib | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| Abemaciclib, Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer | NCT06344780 | Breast Cancer | 18 Years - 75 Years | Fudan University | ||
| Dalpiciclib in HR+/HER2- ABC | NCT06301438 | Advanced Breast... | dalpiciclib | 18 Years - | RenJi Hospital | |
| Dalpiciclib in HR+/HER2- ABC | NCT06301438 | Advanced Breast... | dalpiciclib | 18 Years - | RenJi Hospital | |
| Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy | NCT05806671 | Breast Cancer | Dalpiciclib Pyrotinib Fulvestrant | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer | NCT05463601 | Metastatic Brea... | Mecapegfilgrast... dalpiciclib exemestane, ful... | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | NCT05582499 | Breast Neoplasm Breast Cancer Breast Tumors Triple-Negative... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Dalpiciclib Pyrotinib SHR-A1811 SHR-1316 Camrelizumab Trophoblast cel... Pertuzumab Trastuzumab Goserelin Letrozole Nab paclitaxel Carboplatin Epirubicin Cyclophosphamid... Fluzoparib HER2 ADC | 18 Years - 70 Years | Fudan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
